Amarin Corporation (NASDAQ: AMRN) Stock Trading Halted Today; FDA Advisory Committee to Review sNDA for Vascepa(R) ANCHOR

Amarin Corporation (NASDAQ: AMRN) Stock Trading Halted Today; FDA Advisory
Committee to Review sNDA for Vascepa(R) ANCHOR Indication

BEDMINSTER, N.J., and DUBLIN, Ireland, Oct. 16, 2013 (GLOBE NEWSWIRE) --
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on
the commercialization and development of therapeutics to improve
cardiovascular health, today announced that NASDAQ has halted trading of the
company's shares.

The U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic
Drugs Advisory Committee (EMDAC) is meeting today to openly discuss the
company's supplemental New Drug Application (sNDA) for the proposed ANCHOR
indication for Vascepa® (icosapent ethyl) and Amarin will hold a conference
call at 7:00 pm Eastern time tonight to discuss the meeting (details
previously announced).

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA. For more information about Vascepa visit
www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

Availability of other information about Amarin

Investors and others should note that we communicate with our investors and
the public using our company website (www.amarincorp.com), our investor
relations website (http://www.amarincorp.com/investor-splash.html), including
but not limited to investor presentations and investor FAQs, Securities and
Exchange Commissionfilings, press releases, public conference calls and
webcasts. The information that we post on these channels and websites could be
deemed to be material information. As a result, we encourage investors, the
media, and others interested in Amarin to review the information that we post
on these channels, including our investor relations website, on a regular
basis. This list of channels may be updated from time to time on our investor
relations website and may include social media channels. The contents of our
website or these channels, or any other website that may be accessed from our
website or these channels, shall not be deemed incorporated by reference in
any filing under the Securities Act of 1933.

CONTACT: Amarin contact information:
         Joseph Bruno
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo